CD36: Implications in cardiovascular disease

International Journal of Biochemistry and Cell Biology

Volumn 39, Issue 11, 2007, Pages 2012-2030

  Febbraio, Maria ^a   Silverstein, Roy L ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Angiogenesis; Atherosclerosis; CD36; Inflammation; Scavenger receptor

Indexed keywords

AMYLOID BETA PROTEIN; CD36 ANTIGEN; FATTY ACID; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEMBRANE PROTEIN; THROMBOSPONDIN;

ANTIGEN EXPRESSION; APOPTOSIS; BACTERIAL CELL WALL; CARDIOVASCULAR DISEASE; DENDRITIC CELL; ENDOTHELIUM CELL; ERYTHROCYTE; GRAM POSITIVE BACTERIUM; HEART; HUMAN; LIGAND BINDING; MACROPHAGE ACTIVATION; MALARIA; MUSCLE TISSUE; PROTEIN INTAKE; PROTEIN MODIFICATION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ANTIGENS, CD36; CARDIOVASCULAR DISEASES; HUMANS; INSULIN RESISTANCE;

BACTERIA (MICROORGANISMS); POSIBACTERIA;

EID: 34548482011     PISSN: 13572725     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biocel.2007.03.012     Document Type: Review

References (206)

1. Abumrad N.A., el-Maghrabi M.R., Amri E.Z., Lopez E., and Grimaldi P.A. Cloning of a rat adipocyte membrane protein implicated in binding or transport of long-chain fatty acids that is induced during preadipocyte differentiation. Homology with human CD36. J. Biol. Chem. 268 (1993) 17665-17668
2. Acton S., Rigotti A., Landschulz K.T., Xu S., Hobbs H.H., and Krieger M. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science 271 (1996) 518-520
3. Adams J.C., and Lawler J. The thrombospondins. Int. J. Biochem. Cell. Biol. 36 (2004) 961-968
4. Aitman T.J., Glazier A.M., Wallace C.A., Cooper L.D., Norsworthy P.J., Wahid F.N., et al. Identification of Cd36 (Fat) as an insulin-resistance gene causing defective fatty acid and glucose metabolism in hypertensive rats. Nat. Genet. 21 (1999) 76-83
5. Aitman T.J., Cooper L.D., Norsworthy P.J., Wahid F.N., Gray J.K., Curtis B.R., et al. Malaria susceptibility and CD36 mutation. Nature 405 (2000) 1015-1016
6. Albert M.L., Pearce S.F., Francisco L.M., Sauter B., Roy P., Silverstein R.L., et al. Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J. Exp. Med. 188 (1998) 1359-1368
7. Allen M.H., Barker J.N., and MacDonald D.M. Keratinocyte expression of CD36 antigen in benign and malignant epidermal cell-derived tumours. J. Cutan. Pathol. 18 (1991) 198-203
8. Allred K.F., Smart E.J., and Wilson M.E. Estrogen receptor-alpha mediates gender differences in atherosclerosis induced by HIV protease inhibitors. J. Biol. Chem. 281 (2006) 1419-1425
9. Asch A.S., Liu I., Briccetti F.M., Barnwell J.W., Kwakye-Berko F., Dokun A., et al. Analysis of CD36 binding domains: Ligand specificity controlled by dephosphorylation of an ectodomain. Science 262 (1993) 1436-1440
10. Baillie A.G.S., Coburn C.T., and Abumrad N.A. Reversible binding of long-chain fatty acids to purified FAT, the adipose CD36 homolog. J. Membr. Biol. 153 (1996) 75-81
11. Bamberger M.E., Harris M.E., McDonald D.R., Husemann J., and Landreth G.E. A cell surface receptor complex for fibrillar beta-amyloid mediates microglial activation. J. Neurosci. 23 (2003) 2665-2674
12. Basta G., Schmidt A.M., and De Caterina R. Advanced glycation end products and vascular inflammation: Implications for accelerated atherosclerosis in diabetes. Cardiovasc. Res. 63 (2004) 582-592
13. Bastie C.C., Nahle Z., McLoughlin T., Esser K., Zhang W., Unterman T., et al. FoxO1 stimulates fatty acid uptake and oxidation in muscle cells through CD36-dependent and -independent mechanisms. J. Biol. Chem. 280 (2005) 14222-14229
14. Benton C.R., Koonen D.P., Calles-Escandon J., Tandon N.N., Glatz J.F., Luiken J.J., et al. Differential effects of contraction and PPAR agonists on the expression of fatty acid transporters in rat skeletal muscle. J. Physiol. 573 (2006) 199-210
15. Benton C.R., Han X.X., Febbraio M., Graham T.E., and Bonen A. Inverse relationship between PGC-1alpha protein expression and triacylglycerol accumulation in rodent skeletal muscle. J. Appl. Physiol. 100 (2006) 377-383
16. Bodart V., Febbraio M., Demers A., McNicoll N., Pohankova P., Perreault A., et al. CD36 mediates the cardiovascular action of growth hormone-releasing peptides in the heart. Circ. Res. 90 (2002) 844-849
17. Bolin R.B., Medina F., and Cheney B.A. Glycoprotein changes in fresh vs. room temperature-stored platelets and their buoyant density cohorts. J. Lab. Clin. Med. 98 (1981) 500-510
18. Bonen A., Parolin M.L., Steinberg G.R., Calles-Escandon J., Tandon N.N., Glatz J.F., et al. Triacylglycerol accumulation in human obesity and type 2 diabetes is associated with increased rates of skeletal muscle fatty acid transport and increased sarcolemmal FAT/CD36. FASEB J. 18 (2004) 1144-1146
19. Brownlee M. The pathobiology of diabetic complications: A unifying mechanism. Diabetes 54 (2005) 1615-1625
20. Bruni F., Pasqui A.L., Pastorelli M., Bova G., Cercignani M., Palazzuoli A., et al. Different effect of statins on platelet oxidized-LDL receptor (CD36 and LOX-1) expression in hypercholesterolemic subjects. Clin. Appl. Thromb. Hemost. 11 (2005) 417-428
21. Calvo D., Gomez-Coronado D., Suarez Y., Lasuncion M.A., and Vega M.A. Human CD36 is a high affinity receptor for the native lipoproteins HDL, LDL, and VLDL. J. Lipid Res. 39 (1998) 777-788
22. Cameron-Smith D., Burke L.M., Angus D.J., Tunstall R.J., Cox G.R., Bonen A., et al. A short-term, high-fat diet up-regulates lipid metabolism and gene expression in human skeletal muscle. Am. J. Clin. Nutr. 77 (2003) 313-318
23. Chabowski A., Coort S.L., Calles-Escandon J., Tandon N.N., Glatz J.F., Luiken J.J., et al. Insulin stimulates fatty acid transport by regulating expression of FAT/CD36 but not FABPpm. Am. J. Physiol. Endocrinol. Metab. 287 (2004) E781-E789
24. Chabowski A., Coort S.L., Calles-Escandon J., Tandon N.N., Glatz J.F., Luiken J.J., et al. The subcellular compartmentation of fatty acid transporters is regulated differently by insulin and by AICAR. FEBS Lett. 579 (2005) 2428-2432
25. Chabowski A., Momken I., Coort S.L., Calles-Escandon J., Tandon N.N., Glatz J.F., et al. Prolonged AMPK activation increases the expression of fatty acid transporters in cardiac myocytes and perfused hearts. Mol. Cell. Biochem. 288 (2006) 201-212
26. Chabowski A., Gorski J., Calles-Escandon J., Tandon N.N., and Bonen A. Hypoxia-induced fatty acid transporter translocation increases fatty acid transport and contributes to lipid accumulation in the heart. FEBS Lett. 580 (2006) 3617-3623
27. Chawla A., Boisvert W.A., Lee C.H., Laffitte B.A., Barak Y., Joseph S.B., et al. A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol. Cell. 7 (2001) 161-171
28. Chen C.H., Cartwright Jr. J., Li Z., Lou S., Nguyen H.H., and Gotto Jr. A.M. Inhibitory effects of hypercholesterolemia and ox-LDL on angiogenesis-like endothelial growth in rabbit aortic explants. Essential role of basic fibroblast growth factor. Arterioscler. Thromb. Vasc. Biol. 17 (1997) 1303-1312
29. Chen M., Yang Y., Braunstein E., Georgeson K.E., and Harmon C.M. Gut expression and regulation of FAT/CD36: Possible role in fatty acid transport in rat enterocytes. Am. J. Physiol. Endocrinol. Metab. 281 (2001) E916-E923
30. Chen M., Yang Y.K., Loux T.J., Georgeson K.E., and Harmon C.M. The role of hyperglycemia in FAT/CD36 expression and function. Pediatr. Surg. Int. 22 (2006) 647-654
31. Chinetti G., Lestavel S., Bocher V., Remaley A.T., Neve B., Torra I.P., et al. PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat. Med. 7 (2001) 53-58
32. Cho S., Park E.M., Febbraio M., Anrather J., Park L., Racchumi G., et al. The class B scavenger receptor CD36 mediates free radical production and tissue injury in cerebral ischemia. J. Neurosci. 25 (2005) 2504-2512
33. Clezardin P., Frappart L., Clerget M., Pechoux C., and Delmas P.D. Expression of thrombospondin (TSP1) and its receptors (CD36 and CD51) in normal, hyperplastic, and neoplastic human breast. Cancer Res. 53 (1993) 1421-1430
34. Coburn C.T., Knapp Jr. F.F., Febbraio M., Beets A.L., Silverstein R.L., and Abumrad N.A. Defective uptake and utilization of long chain fatty acids in muscle and adipose tissues of CD36 knockout mice. J. Biol. Chem. 275 (2000) 32523-32529
35. Collison M., Glazier A.M., Graham D., Morton J.J., Dominiczak M.H., Aitman T.J., et al. Cd36 and molecular mechanisms of insulin resistance in the stroke-prone spontaneously hypertensive rat. Diabetes 49 (2000) 2222-2226
36. Coort S.L., Hasselbaink D.M., Koonen D.P., Willems J., Coumans W.A., Chabowski A., et al. Enhanced sarcolemmal FAT/CD36 content and triacylglycerol storage in cardiac myocytes from obese zucker rats. Diabetes 53 (2004) 1655-1663
37. Corpeleijn E., van der Kallen C.J., Kruijshoop M., Magagnin M.G., de Bruin T.W., Feskens E.J., et al. Direct association of a promoter polymorphism in the CD36/FAT fatty acid transporter gene with Type 2 diabetes mellitus and insulin resistance. Diab. Med. 23 (2006) 907-911
38. Crombie R., and Silverstein R. Lysosomal integral membrane protein II binds thrombospondin-1. Structure-function homology with the cell adhesion molecule CD36 defines a conserved recognition motif. J. Biol. Chem. 273 (1998) 4855-4863
39. Curtiss L.K. Is two out of three enough for ABCG1?. Arterioscler. Thromb. Vasc. Biol. 26 (2006) 2175-2177
40. Daviet L., Buckland R., Puente Navazo M.D., and McGregor J.L. Identification of an immunodominant functional domain on human CD36 antigen using human-mouse chimaeric proteins and homologue-replacement mutagenesis. Biochem. J. 305 (1995) 221-224
41. Dawson D.W., Volpert O.V., Pearce S.F., Schneider A.J., Silverstein R.L., Henkin J., et al. Three distinct d-amino acid substitutions confer potent antiangiogenic activity on an inactive peptide derived from a thrombospondin-1 type 1 repeat. Mol. Pharmacol. 55 (1999) 332-338
42. Dawson D.W., Pearce S.F., Zhong R., Silverstein R.L., Frazier W.A., and Bouck N.P. CD36 mediates the in vitro inhibitory effects of thrombospondin-1 on endothelial cells. J. Cell. Biol. 138 (1997) 707-717
43. Demers A., McNicoll N., Febbraio M., Servant M., Marleau S., Silverstein R., et al. Identification of the growth hormone-releasing peptide binding site in CD36: A photoaffinity cross-linking study. Biochem. J. 382 (2004) 417-424
44. de Oliveira Silva, C., Delbosc, S., Arais, C., Monnier, L., Cristol, J. P., & Pares-Herbute, N. (2006). Modulation of CD36 protein expression by AGEs and insulin in aortic VSMCs from diabetic and non-diabetic rats. Nutr. Metab. Cardiovasc. Dis., epub.
45. Dorahy D.J., Lincz L.F., Meldrum C.J., and Burns G.F. Biochemical isolation of a membrane microdomain from resting platelets highly enriched in the plasma membrane glycoprotein CD36. Biochem. J. 319 (1996) 67-72
46. Dressman J., Kincer J., Matveev S.V., Guo L., Greenberg R.N., Guerin T., et al. HIV protease inhibitors promote atherosclerotic lesion formation independent of dyslipidemia by increasing CD36-dependent cholesteryl ester accumulation in macrophages. J. Clin. Invest. 111 (2003) 389-397
47. El Khoury J.B., Moore K.J., Means T.K., Leung J., Terada K., Toft M., et al. CD36 mediates the innate host response to beta-amyloid. J. Exp. Med. 197 (2003) 1657-1666
48. Endemann G., Stanton L.W., Madden K.S., Bryant C.M., White R.T., and Protter A.A. CD36 is a receptor for oxidized low density lipoprotein. J. Biol. Chem. 268 (1993) 11811-11816
49. Englyst N.A., Taube J.M., Aitman T.J., Baglin T.P., and Byrne C.D. A novel role for CD36 in VLDL-enhanced platelet activation. Diabetes 52 (2003) 1248-1255
50. Eyre N.S., Cleland L.G., Tandon N.N., and Mayrhofer G. Involvement of the C-terminal cytoplasmic domain in the plasma membrane localization of FAT/CD36 and its ability to mediate long-chain fatty acid uptake. J. Lipid Res. 48 (2007) 528-542
51. Fadok V.A., Bratton D.L., Frasch S.C., Warner M.L., and Henson P.M. The role of phosphatidylserine in recognition of apoptotic cells by phagocytes. Cell. Death Differ. 5 (1998) 551-562
52. Farhangkhoee H., Khan Z.A., Barbin Y., and Chakrabarti S. Glucose-induced up-regulation of CD36 mediates oxidative stress and microvascular endothelial cell dysfunction. Diabetologia 48 (2005) 1401-1410
53. Febbraio M., Abumrad N.A., Hajjar D.P., Sharma K., Cheng W., Pearce S.F., et al. A null mutation in murine CD36 reveals an important role in fatty acid and lipoprotein metabolism. J. Biol. Chem. 274 (1999) 19055-19062
54. Febbraio M., Podrez E.A., Smith J.D., Hajjar D.P., Hazen S.L., Hoff H.F., et al. Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. J. Clin. Invest. 105 (2000) 1049-1056
55. Febbraio M., Guy E., and Silverstein R.L. Stem cell transplantation reveals that absence of macrophage CD36 is protective against atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 24 (2004) 2333-2338
56. Feng J., Han J., Pearce S.F., Silverstein R.L., Gotto Jr. A.M., Hajjar D.P., et al. Induction of CD36 expression by oxidized LDL and IL-4 by a common signaling pathway dependent on protein kinase C and PPAR-gamma. J. Lipid Res. 41 (2000) 688-696
57. Fernandez-Ruiz E., Armesilla A.L., Sanchez-Madrid F., and Vega M.A. Gene encoding the collagen type I and thrombospondin receptor CD36 is located on chromosome 7q11.2. Genomics 17 (1993) 759-761
58. Forbes J.M., Soldatos G., and Thomas M.C. Below the radar: Advanced glycation end products that detour "around the side". Is HbA1c not an accurate enough predictor of long term progression and glycaemic control in diabetes?. Clin. Biochem. Rev. 26 (2005) 123-134
59. Franc N.C., Dimarcq J.L., Lagueux M., Hoffmann J., and Ezekowitz R.A. Croquemort, a novel Drosophila hemocyte/macrophage receptor that recognizes apoptotic cells. Immunity 4 (1996) 431-443
60. Franc N.C., Heitzler P., Ezekowitz R.A., and White K. Requirement for croquemort in phagocytosis of apoptotic cells in Drosophila. Science 284 (1999) 1991-1994
61. Frank P.G., Lee H., Park D.S., Tandon N.N., Scherer P.E., and Lisanti M.P. Genetic ablation of caveolin-1 confers protection against atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 24 (2004) 98-105
62. Franke-Fayard B., Janse C.J., Cunha-Rodrigues M., Ramesar J., Buscher P., Que I., et al. Murine malaria parasite sequestration: CD36 is the major receptor, but cerebral pathology is unlinked to sequestration. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 11468-11473
63. Fuhrman B., Koren L., Volkova N., Keidar S., Hayek T., and Aviram M. Atorvastatin therapy in hypercholesterolemic patients suppresses cellular uptake of oxidized-LDL by differentiating monocytes. Atherosclerosis 164 (2002) 179-185
64. Furuhashi M., Ura N., Nakata T., and Shimamoto K. Insulin sensitivity and lipid metabolism in human CD36 deficiency. Diab. Care 26 (2003) 471-474
65. Furuhashi M., Ura N., Nakata T., Tanaka T., and Shimamoto K. Genotype in human CD36 deficiency and diabetes mellitus. Diab. Med 21 (2004) 952-953
66. Gamp A.C., Tanaka Y., Lullmann-Rauch R., Wittke D., D'Hooge R., De Deyn P.P., et al. LIMP-2/LGP85 deficiency causes ureteric pelvic junction obstruction, deafness and peripheral neuropathy in mice. Hum. Mol. Genet. 12 (2003) 631-646
67. Gelhaus A., Scheding A., Browne E., Burchard G.D., and Horstmann R.D. Variability of the CD36 gene in West Africa. Hum. Mutat. 18 (2001) 444-450
68. Gietema J.A., Hoekstra R., de Vos F.Y., Uges D.R., van der Gaast A., Groen H.J., et al. A phase I study assessing the safety and pharmacokinetics of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with gemcitabine and cisplatin in patients with solid tumors. Ann. Oncol. 17 (2006) 1320-1327
69. Glatz J.F., Bonen A., and Luiken J.J. Exercise and insulin increase muscle fatty acid uptake by recruiting putative fatty acid transporters to the sarcolemma. Curr. Opin. Clin. Nutr. Metab. Care 5 (2002) 365-370
70. Gordon S. Pattern recognition receptors: Doubling up for the innate immune response. Cell 111 (2002) 927-930
71. Gotoda T., Iizuka Y., Kato N., Osuga J., Bihoreau M.T., Murakami T., et al. Absence of Cd36 mutation in the original spontaneously hypertensive rats with insulin resistance. Nat. Genet. 22 (1999) 226-228
72. Goudriaan J.R., Dahlmans V.E., Teusink B., Ouwens D.M., Febbraio M., Maassen J.A., et al. CD36 deficiency increases insulin sensitivity in muscle, but induces insulin resistance in the liver in mice. J. Lipid Res. 44 (2003) 2270-2277
73. Goudriaan J.R., den Boer M.A., Rensen P.C., Febbraio M., Kuipers F., Romijn J.A., et al. CD36 deficiency in mice impairs lipoprotein lipase-mediated triglyceride clearance. J. Lipid Res. 46 (2005) 2175-2181
74. Greenberg M.E., Sun M., Zhang R., Febbraio M., Silverstein R., and Hazen S.L. Oxidized phosphatidylserine-CD36 interactions play an essential role in macrophage-dependent phagocytosis of apoptotic cells. J. Exp. Med. 203 (2006) 2613-2625
75. Griffin E., Re A., Hamel N., Fu C., Bush H., McCaffrey T., et al. A link between diabetes and atherosclerosis: Glucose regulates expression of CD36 at the level of translation. Nat. Med. 7 (2001) 840-846
76. Gruarin P., Thorne R.F., Dorahy D.J., Burns G.F., Sitia R., and Alessio M. CD36 is a ditopic glycoprotein with the N-terminal domain implicated in intracellular transport. Biochem. Biophys. Res. Commun. 275 (2000) 446-454
77. Guy, E., Kuchibhotla, S., Silverstein, R., & Febbraio, M. (2007). Continued inhibition of atherosclerotic lesion development in long term Western diet fed CD36 KO/apoE KO mice. Atherosclerosis, epub.
78. Hajri T., Ibrahimi A., Coburn C.T., Knapp Jr. F.F., Kurtz T., Pravenec M., et al. Defective fatty acid uptake in the spontaneously hypertensive rat is a primary determinant of altered glucose metabolism, hyperinsulinemia, and myocardial hypertrophy. J. Biol. Chem. 276 (2001) 23661-23666
79. Han J., Hajjar D.P., Tauras J.M., Feng J., Gotto Jr. A.M., and Nicholson A.C. Transforming growth factor-beta1 (TGF-beta1) and TGF-beta2 decrease expression of CD36, the type B scavenger receptor, through mitogen-activated protein kinase phosphorylation of peroxisome proliferator-activated receptor-gamma. J. Biol. Chem. 275 (2000) 1241-1246
80. Han J., Zhou X., Yokoyama T., Hajjar D.P., Gotto Jr. A.M., and Nicholson A.C. Pitavastatin downregulates expression of the macrophage type B scavenger receptor, CD36. Circulation 109 (2004) 790-796
81. Hashimoto M., Tawaratsumida K., Kariya H., Kiyohara A., Suda Y., Krikae F., et al. Not lipoteichoic acid but lipoproteins appear to be the dominant immunobiologically active compounds in Staphylococcus aureus. J. Immunol. 177 (2006) 3162-3169
82. Hatmi M., Gavaret J.M., Elalamy I., Vargaftig B.B., and Jacquemin C. Evidence for cAMP-dependent platelet ectoprotein kinase activity that phosphorylates platelet glycoprotein IV (CD36). J. Biol. Chem. 271 (1996) 24776-24780
83. Hayek T., Hussein K., Aviram M., Coleman R., Keidar S., Pavoltzky E., et al. Macrophage-foam cell formation in streptozotocin-induced diabetic mice: Stimulatory effect of glucose. Atherosclerosis 183 (2005) 25-33
84. Heather L.C., Cole M.A., Lygate C.A., Evans R.D., Stuckey D.J., Murray A.J., et al. Fatty acid transporter levels and palmitate oxidation rate correlate with ejection fraction in the infarcted rat heart. Cardiovasc. Res. 72 (2006) 430-437
85. Henry P.D. Hypercholesterolemia and angiogenesis. Am. J. Cardiol. 72 (1993) 61C-64C
86. Hirakata M., Tozawa R., Imura Y., and Sugiyama Y. Comparison of the effects of pioglitazone and rosiglitazone on macrophage foam cell formation. Biochem. Biophys. Res. Commun. 323 (2004) 782-788
87. Ho M., Hoang H.L., Lee K.M., Liu N., MacRae T., Montes L., et al. Ectophosphorylation of CD36 regulates cytoadherence of Plasmodium falciparum to microvascular endothelium under flow conditions. Infect. Immun. 73 (2005) 8179-8187
88. Hoebe K., Georgel P., Rutschmann S., Du X., Mudd S., Crozat K., et al. CD36 is a sensor of diacylglycerides. Nature 433 (2005) 523-527
89. Huang H., Campbell S.C., Bedford D.F., Nelius T., Veliceasa D., Shroff E.H., et al. Peroxisome proliferator-activated receptor gamma ligands improve the antitumor efficacy of thrombospondin peptide ABT510. Mol. Cancer Res. 2 (2004) 541-550
90. Huang M.M., Bolen J.B., Barnwell J.W., Shattil S.J., and Brugge J.S. Membrane glycoprotein IV (CD36) is physically associated with the Fyn, Lyn, and Yes protein-tyrosine kinases in human platelets. Proc. Natl. Acad. Sci. U.S.A. 88 (1991) 7844-7848
91. Huh H.Y., Lo S.K., Yesner L.M., and Silverstein R.L. CD36 induction on human monocytes upon adhesion to tumor necrosis factor-activated endothelial cells. J. Biol. Chem. 270 (1995) 6267-6271
92. Huh H.Y., Pearce S.F., Yesner L.M., Schindler J.L., and Silverstein R.L. Regulated expression of CD36 during monocyte-to-macrophage differentiation: Potential role of CD36 in foam cell formation. Blood 87 (1996) 2020-2028
93. Husemann J., Loike J.D., Anankov R., Febbraio M., and Silverstein S.C. Scavenger receptors in neurobiology and neuropathology: Their role on microglia and other cells of the nervous system. Glia 40 (2002) 195-205
94. Hwang E.H., Taki J., Yasue S., Fujimoto M., Taniguchi M., Matsunari I., et al. Absent myocardial iodine-123-BMIPP uptake and platelet/monocyte CD36 deficiency. J. Nucl. Med. 39 (1998) 1681-1684
95. Imanishi T., Hano T., Matsuo Y., and Nishio I. Oxidized low-density lipoprotein inhibits vascular endothelial growth factor-induced endothelial progenitor cell differentiation. Clin. Exp. Pharmacol. Physiol. 30 (2003) 665-670
96. Irie H., Krukenkamp I.B., Brinkmann J.F., Gaudette G.R., Saltman A.E., Jou W., et al. Myocardial recovery from ischemia is impaired in CD36-null mice and restored by myocyte CD36 expression or medium-chain fatty acids. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 6819-6824
97. Iruela-Arispe M.L., Lombardo M., Krutzsch H.C., Lawler J., and Roberts D.D. Inhibition of angiogenesis by thrombospondin-1 is mediated by 2 independent regions within the type 1 repeats. Circulation 100 (1999) 1423-1431
98. Jimenez B., Volpert O.V., Crawford S.E., Febbraio M., Silverstein R.L., and Bouck N. Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat. Med. 6 (2000) 41-48
99. Jochen A., and Hays J. Purification of the major substrate for palmitoylation in rat adipocytes: N-terminal homology with CD36 and evidence for cell surface acylation. J. Lipid Res. 34 (1993) 1783-1792
100. Kajihara S., Hisatomi A., Ogawa Y., Yasutake T., Yoshimura T., Hara T., et al. Association of the Pro90Ser CD36 mutation with elevated free fatty acid concentrations but not with insulin resistance syndrome in Japanese. Clin. Chim. Acta 314 (2001) 125-130
101. Kieffer N., Nurden A.T., Hasitz M., Titeux M., and Breton-Gorius J. Identification of platelet membrane thrombospondin binding molecules using an anti-thrombospondin antibody. Biochim. Biophys. Acta 967 (1988) 408-415
102. Kincer J.F., Uittenbogaard A., Dressman J., Guerin T.M., Febbraio M., Guo L., et al. Hypercholesterolemia promotes a CD36-dependent and endothelial nitric-oxide synthase-mediated vascular dysfunction. J. Biol. Chem. 277 (2002) 23525-23533
103. Kolak M., Yki-Jarvinen H., Kannisto K., Tiikkainen M., Hamsten A., Eriksson P., et al. Effects of chronic rosiglitazone therapy on gene expression in human adipose tissue in vivo in patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 92 (2007) 720-724
104. Koonen D.P., Benton C.R., Arumugam Y., Tandon N.N., Calles-Escandon J., Glatz J.F., et al. Different mechanisms can alter fatty acid transport when muscle contractile activity is chronically altered. Am. J. Physiol. Endocrinol. Metab. 286 (2004) E1042-E1049
105. Koonen D.P., Glatz J.F., Bonen A., and Luiken J.J. Long-chain fatty acid uptake and FAT/CD36 translocation in heart and skeletal muscle. Biochim. Biophys. Acta 1736 (2005) 163-180
106. Krieger M. The other side of scavenger receptors: Pattern recognition for host defense. Curr. Opin. Lipidol. 8 (1997) 275-280
107. Kuang M., Febbraio M., Wagg C., Lopaschuk G.D., and Dyck J.R. Fatty acid translocase/CD36 deficiency does not energetically or functionally compromise hearts before or after ischemia. Circulation 109 (2004) 1550-1557
108. Kunjathoor V.V., Febbraio M., Podrez E.A., Moore K.J., Andersson L., Koehn S., et al. Scavenger receptors class A-I/II and CD36 are the principal receptors responsible for the uptake of modified low density lipoprotein leading to lipid loading in macrophages. J. Biol. Chem. 277 (2002) 49982-49988
109. Kuwasako T., Hirano K., Sakai N., Ishigami M., Hiraoka H., Yakub M.J., et al. Lipoprotein abnormalities in human genetic CD36 deficiency associated with insulin resistance and abnormal fatty acid metabolism. Diab. Care 26 (2003) 1647-1648
110. Kwok C.F., Juan C.C., and Ho L.T. Endothelin-1 decreases CD36 protein expression in vascular smooth muscle cells. Am. J. Physiol. Endocrinol. Metab. 292 (2007) E648-E652
111. Laugerette F., Passilly-Degrace P., Patris B., Niot I., Febbraio M., Montmayeur J.P., et al. CD36 involvement in orosensory detection of dietary lipids, spontaneous fat preference, and digestive secretions. J. Clin. Invest. 115 (2005) 3177-3184
112. Lee K., Godeau B., Fromont P., Plonquet A., Debili N., Bachir D., et al. CD36 deficiency is frequent and can cause platelet immunization in Africans. Transfusion 39 (1999) 873-879
113. Lepretre F., Linton K.J., Lacquemant C., Vatin V., Samson C., Dina C., et al. Genetic study of the CD36 gene in a French diabetic population. Diabetes Metab. 30 (2004) 459-463
114. Lepretre F., Vasseur F., Vaxillaire M., Scherer P.E., Ali S., Linton K., et al. A CD36 nonsense mutation associated with insulin resistance and familial type 2 diabetes. Hum. Mutat. 24 (2004) 104
115. Li A.C., Brown K.K., Silvestre M.J., Willson T.M., Palinski W., and Glass C.K. Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J. Clin. Invest. 106 (2000) 523-531
116. Lim H.J., Lee S., Lee K.S., Park J.H., Jang Y., Lee E.J., et al. PPAR gamma activation induces CD36 expression and stimulates foam cell like changes in rVSMCs. Prostaglandins Other Lipid Mediat. 80 (2006) 165-174
117. Llaverias G., Rebollo A., Pou J., Vazquez-Carrera M., Sanchez R.M., Laguna J.C., et al. Effects of rosiglitazone and atorvastatin on the expression of genes that control cholesterol homeostasis in differentiating monocytes. Biochem. Pharmacol. 71 (2006) 605-614
118. Lucas M., Stuart L.M., Zhang A., Hodivala-Dilke K., Febbraio M., Silverstein R., et al. Requirements for apoptotic cell contact in regulation of macrophage responses. J. Immunol. 177 (2006) 4047-4054
119. Luiken J.J., Dyck D.J., Han X.X., Tandon N.N., Arumugam Y., Glatz J.F., et al. Insulin stimulates long-chain fatty acid utilization by rat cardiac myocytes through cellular redistribution of FAT/CD36. Diabetes 51 (2002) 3113-3119
120. Lyle A.N., and Griendling K.K. Modulation of vascular smooth muscle signaling by reactive oxygen species. Physiology 21 (2006) 269-280
121. Ma X., Bacci S., Mlynarski W., Gottardo L., Soccio T., Menzaghi C., et al. A common haplotype at the CD36 locus is associated with high free fatty acid levels and increased cardiovascular risk in Caucasians. Hum. Mol. Genet. 13 (2004) 2197-2205
122. Malaud E., Hourton D., Giroux L.M., Ninio E., Buckland R., and McGregor J.L. The terminal six amino acids of the carboxy cytoplasmic tail of CD36 contain a functional domain implicated in the binding and capture of oxidized low-density lipoprotein. Biochem. J. 364 (2002) 507-515
123. Marleau S., Harb D., Bujold K., Avallone R., Iken K., Wang Y., et al. EP 80317 a ligand of the CD36 scavenger receptor, protects apolipoprotein E-deficient mice from developing atherosclerotic lesions. FASEB J. 19 (2005) 1869-1871
124. Mauldin J.P., Srinivasan S., Mulya A., Gebre A., Parks J.S., Daugherty A., et al. Reduction in ABCG1 in Type 2 diabetic mice increases macrophage foam cell formation. J. Biol. Chem. 281 (2006) 21216-21224
125. Medeiros L.A., Khan T., El Khoury J.B., Pham C.L., Hatters D.M., Howlett G.J., et al. Fibrillar amyloid protein present in atheroma activates CD36 signal transduction. J. Biol. Chem. 279 (2004) 10643-10648
126. Memon R.A., Feingold K.R., Moser A.H., Fuller J., and Grunfeld C. Regulation of fatty acid transport protein and fatty acid translocase mRNA levels by endotoxin and cytokines. Am. J. Physiol. 274 (1998) E210-E217
127. Miao W.M., Seng W.L., Duquette M., Lawler P., Laus C., and Lawler J. Thrombospondin-1 type 1 repeat recombinant proteins inhibit tumor growth through transforming growth factor-beta-dependent and -independent mechanisms. Cancer Res. 61 (2001) 7830-7839
128. Miyaoka K., Kuwasako T., Hirano K., Nozaki S., Yamashita S., and Matsuzawa Y. CD36 deficiency associated with insulin resistance. Lancet 357 (2001) 686-687
129. Moore K.J., El Khoury J., Medeiros L.A., Terada K., Geula C., Luster A.D., et al. A CD36-initiated signaling cascade mediates inflammatory effects of beta-amyloid. J. Biol. Chem. 277 (2002) 47373-47379
130. Moore K.J., Kunjathoor V.V., Koehn S.L., Manning J.J., Tseng A.A., Silver J.M., et al. Loss of receptor-mediated lipid uptake via scavenger receptor A or CD36 pathways does not ameliorate atherosclerosis in hyperlipidemic mice. J. Clin. Invest. 115 (2005) 2192-2201
131. Motojima K., Passilly P., Peters J.M., Gonzalez F.J., and Latruffe N. Expression of putative fatty acid transporter genes are regulated by peroxisome proliferator-activated receptor alpha and gamma activators in a tissue- and inducer-specific manner. J. Biol. Chem. 273 (1998) 16710-16714
132. Moulton K.S., Vakili K., Zurakowski D., Soliman M., Butterfield C., Sylvin E., et al. Inhibition of plaque neovascularization reduces macrophage accumulation and progression of advanced atherosclerosis. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 4736-4741
133. Munteanu A., Zingg J.M., Ricciarelli R., and Azzi A. CD36 overexpression in ritonavir-treated THP-1 cells is reversed by alpha-tocopherol. Free Radic. Biol. Med. 38 (2005) 1047-1056
134. Mwaikambo B.R., Sennlaub F., Ong H., Chemtob S., and Hardy P. Activation of CD36 inhibits and induces regression of inflammatory corneal neovascularization. Invest. Ophthalmol. Vis. Sci. 47 (2006) 4356-4364
135. Nakagawa T., Nozaki S., Nishida M., Yakub J.M., Tomiyama Y., Nakata A., et al. Oxidized LDL increases and interferon-gamma decreases expression of CD36 in human monocyte-derived macrophages. Arterioscler. Thromb. Vasc. Biol. 18 (1998) 1350-1357
136. Navazo M.D., Daviet L., Savill J., Ren Y., Leung L.L., and McGregor J.L. Identification of a domain (155-183) on CD36 implicated in the phagocytosis of apoptotic neutrophils. J. Biol. Chem. 271 (1996) 15381-15385
137. NCBI, SNP database, http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?locusId=948.
138. Ohgami N., Nagai R., Ikemoto M., Arai H., Kuniyasu A., Horiuchi S., et al. Cd36, a member of the class b scavenger receptor family, as a receptor for advanced glycation end products. J. Biol. Chem. 276 (2001) 3195-3202
139. Oquendo P., Hundt E., Lawler J., and Seed B. CD36 directly mediates cytoadherence of Plasmodium falciparum parasitized erythrocytes. Cell 58 (1989) 95-101
140. Out R., Hoekstra M., Hildebrand R.B., Kruit J.K., Meurs I., Li Z., et al. Macrophage ABCG1 deletion disrupts lipid homeostasis in alveolar macrophages and moderately influences atherosclerotic lesion development in LDL receptor-deficient mice. Arterioscler. Thromb. Vasc. Biol. 26 (2006) 2295-2300
141. Pearce S.F., Roy P., Nicholson A.C., Hajjar D.P., Febbraio M., and Silverstein R.L. Recombinant glutathione S-transferase/CD36 fusion proteins define an oxidized low density lipoprotein-binding domain. J. Biol. Chem. 273 (1998) 34875-34881
142. Pearce S.F., Wu J., and Silverstein R.L. Recombinant GST/CD36 fusion proteins define a thrombospondin binding domain. Evidence for a single calcium-dependent binding site on CD36. J. Biol. Chem. 270 (1995) 2981-2986
143. Pietsch A., Erl W., and Lorenz R.L. Lovastatin reduces expression of the combined adhesion and scavenger receptor CD36 in human monocytic cells. Biochem. Pharmacol. 52 (1996) 433-439
144. Pittoni V., and Valesini G. The clearance of apoptotic cells: Implications for autoimmunity. Autoimmun. Rev. 1 (2002) 154-161
145. Platt N., and Gordon S. Scavenger receptors: Diverse activities and promiscuous binding of polyanionic ligands. Chem. Biol. 5 (1998) R193-R203
146. Podrez E.A., Febbraio M., Sheibani N., Schmitt D., Silverstein R.L., Hajjar D.P., et al. Macrophage scavenger receptor CD36 is the major receptor for LDL modified by monocyte-generated reactive nitrogen species. J. Clin. Invest. 105 (2000) 1095-1108
147. Podrez E.A., Poliakov E., Shen Z., Zhang R., Deng Y., Sun M., et al. Identification of a novel family of oxidized phospholipids that serve as ligands for the macrophage scavenger receptor CD36. J. Biol. Chem. 277 (2002) 38503-38516
148. Podrez E.A., Poliakov E., Shen Z., Zhang R., Deng Y., Sun M., et al. A novel family of atherogenic oxidized phospholipids promotes macrophage foam cell formation via the scavenger receptor CD36 and is enriched in atherosclerotic lesions. J. Biol. Chem. 277 (2002) 38517-38523
149. Pohl J., Ring A., Korkmaz U., Ehehalt R., and Stremmel W. FAT/CD36-mediated long-chain fatty acid uptake in adipocytes requires plasma membrane rafts. Mol. Biol. Cell. 16 (2005) 24-31
150. Pravenec M., Zidek V., Simakova M., Kren V., Krenova D., Horky K., et al. Genetics of Cd36 and the clustering of multiple cardiovascular risk factors in spontaneous hypertension. J. Clin. Invest. 103 (1999) 1651-1657
151. Pravenec M., Landa V., Zidek V., Musilova A., Kren V., Kazdova L., et al. Transgenic rescue of defective Cd36 ameliorates insulin resistance in spontaneously hypertensive rats. Nat. Genet. 27 (2001) 156-158
152. Prieto J., Eklund A., and Patarroyo M. Regulated expression of integrins and other adhesion molecules during differentiation of monocytes into macrophages. Cell Immunol. 156 (1994) 191-211
153. Primo L., Ferrandi C., Roca C., Marchio S., di Blasio L., Alessio M., et al. Identification of CD36 molecular features required for its in vitro angiostatic activity. FASEB J. 19 (2005) 1713-1715
154. Puccetti L., Sawamura T., Pasqui A.L., Pastorelli M., Auteri A., and Bruni F. Atorvastatin reduces platelet-oxidized-LDL receptor expression in hypercholesterolaemic patients. Eur. J. Clin. Invest. 35 (2005) 47-51
155. Puente Navazo M.D., Daviet L., Ninio E., and McGregor J.L. Identification on human CD36 of a domain (155-183) implicated in binding oxidized low-density lipoproteins (Ox-LDL). Arterioscler. Thromb. Vasc. Biol. 16 (1996) 1033-1039
156. Rahaman S.O., Lennon D.J., Febbraio M., Podrez E.A., Hazen S.L., and Silverstein R.L. A CD36-dependent signaling cascade is necessary for macrophage foam cell formation. Cell. Metab. 4 (2006) 211-221
157. Ricci R., Sumara G., Sumara I., Rozenberg I., Kurrer M., Akhmedov A., et al. Requirement of JNK2 for scavenger receptor A-mediated foam cell formation in atherogenesis. Science 306 (2004) 1558-1561
158. Ring A., Le Lay S., Pohl J., Verkade P., and Stremmel W. Caveolin-1 is required for fatty acid translocase (FAT/CD36) localization and function at the plasma membrane of mouse embryonic fibroblasts. Biochim. Biophys. Acta 1761 (2006) 416-423
159. Rouabhia M., Jobin N., Doucet Jr. R., Bergeron J., and Auger F.A. CD36(+)-dendritic epidermal cells: A putative actor in the cutaneous immune system. Cell Transplant. 3 (1994) 529-536
160. Rubic T., and Lorenz R.L. Downregulated CD36 and oxLDL uptake and stimulated ABCA1/G1 and cholesterol efflux as anti-atherosclerotic mechanisms of interleukin-10. Cardiovasc. Res. 69 (2006) 527-535
161. Ruiz-Velasco N., Dominguez A., and Vega M.A. Statins upregulate CD36 expression in human monocytes, an effect strengthened when combined with PPAR-gamma ligands. Putative contribution of Rho GTPases in statin-induced CD36 expression. Biochem. Pharmacol. 67 (2004) 303-313
162. Rusk A., McKeegan E., Haviv F., Majest S., Henkin J., and Khanna C. Preclinical evaluation of antiangiogenic thrombospondin-1 peptide mimetics, ABT-526 and ABT-510, in companion dogs with naturally occurring cancers. Clin. Cancer Res. 12 (2006) 7444-7455
163. Ryeom S.W., Silverstein R.L., Scotto A., and Sparrow J.R. Binding of anionic phospholipids to retinal pigment epithelium may be mediated by the scavenger receptor CD36. J. Biol. Chem. 271 (1996) 20536-20539
164. Ryeom S.W., Sparrow J.R., and Silverstein R.L. CD36 participates in the phagocytosis of rod outer segments by retinal pigment epithelium. J. Cell. Sci. 109 (1996) 387-395
165. Sampson M.J., Davies I.R., Braschi S., Ivory K., and Hughes D.A. Increased expression of a scavenger receptor (CD36) in monocytes from subjects with Type 2 diabetes. Atherosclerosis 167 (2003) 129-134
166. Savill J., Hogg N., Ren Y., and Haslett C. Thrombospondin cooperates with CD36 and the vitronectin receptor in macrophage recognition of neutrophils undergoing apoptosis. J. Clin. Invest. 90 (1992) 1513-1522
167. Serghides L., Nathoo S., Walmsley S., and Kain K.C. CD36 deficiency induced by antiretroviral therapy. AIDS 16 (2002) 353-358
168. Serghides L., Smith T.G., Patel S.N., and Kain K.C. CD36 and malaria: Friends or foes?. Trends Parasitol. 19 (2003) 461-469
169. Sfeir Z., Ibrahimi A., Amri E., Grimaldi P., and Abumrad N. Regulation of FAT/CD36 gene expression: Further evidence in support of a role of the protein in fatty acid binding/transport. Prostaglandins Leukot. Essent. Fatty Acids 57 (1997) 17-21
170. Simantov R., Febbraio M., and Silverstein R.L. The antiangiogenic effect of thrombospondin-2 is mediated by CD36 and modulated by histidine-rich glycoprotein. Matrix Biol. 24 (2005) 27-34
171. Spitsberg V.L., Matitashvili E., and Gorewit R.C. Association and coexpression of fatty acid-binding protein and glycoprotein CD36 in the bovine mammary gland. Eur. J. Biochem. 230 (1995) 872-878
172. Stewart C.R., Tseng A.A., Mok Y.F., Staples M.K., Schiesser C.H., Lawrence L.J., et al. Oxidation of low-density lipoproteins induces amyloid-like structures that are recognized by macrophages. Biochemistry 44 (2005) 9108-9116
173. Stuart L.M., Deng J., Silver J.M., Takahashi K., Tseng A.A., Hennessy E.J., et al. Response to Staphylococcus aureus requires CD36-mediated phagocytosis triggered by the COOH-terminal cytoplasmic domain. J. Cell. Biol. 170 (2005) 477-485
174. Sugihara K., Sugihara T., Mohandas N., and Hebbel R.P. Thrombospondin mediates adherence of CD36+ sickle reticulocytes to endothelial cells. Blood 80 (1992) 2634-2642
175. Sun M., Finnemann S.C., Febbraio M., Shan L., Annangudi S.P., Podrez E.A., et al. Light-induced oxidation of photoreceptor outer segment phospholipids generates ligands for CD36-mediated phagocytosis by retinal pigment epithelium: A potential mechanism for modulating outer segment phagocytosis under oxidant stress conditions. J. Biol. Chem. 281 (2006) 4222-4230
176. Susztak K., Ciccone E., McCue P., Sharma K., and Bottinger E.P. Multiple metabolic hits converge on CD36 as novel mediator of tubular epithelial apoptosis in diabetic nephropathy. PLoS Med. 2 (2005) e45
177. Swerlick R.A., Lee K.H., Wick T.M., and Lawley T.J. Human dermal microvascular endothelial but not human umbilical vein endothelial cells express CD36 in vivo and in vitro. J. Immunol. 148 (1992) 78-83
178. Tanaka T., Nakata T., Oka T., Ogawa T., Okamoto F., Kusaka Y., et al. Defect in human myocardial long-chain fatty acid uptake is caused by FAT/CD36 mutations. J. Lipid Res. 42 (2001) 751-759
179. Tandon N.N., Lipsky R.H., Burgess W.H., and Jamieson G.A. Isolation and characterization of platelet glycoprotein IV (CD36). J. Biol. Chem. 264 (1989) 7570-7575
180. Tao N., Wagner S.J., and Lublin D.M. CD36 is palmitoylated on both N- and C-terminal cytoplasmic tails. J. Biol. Chem. 271 (1996) 22315-22320
181. Taylor K.T., Tang Y., Sobieski D.A., and Lipsky R.H. Characterization of two alternatively spliced 5′-untranslated exons of the human CD36 gene in different cell types. Gene 133 (1993) 205-212
182. Thorne R.F., Law E.G., Elith C.A., Ralston K.J., Bates R.C., and Burns G.F. The association between CD36 and Lyn protein tyrosine kinase is mediated by lipid. Biochem. Biophys. Res. Commun. 351 (2006) 51-56
183. Tirziu D., Moodie K.L., Zhuang Z.W., Singer K., Helisch A., Dunn J.F., et al. Delayed arteriogenesis in hypercholesterolemic mice. Circulation 112 (2005) 2501-2509
184. Tontonoz P., and Nagy L. Regulation of macrophage gene expression by peroxisome-proliferator-activated receptor gamma: Implications for cardiovascular disease. Curr. Opin. Lipidol. 10 (1999) 485-490
185. Tontonoz P., Nagy L., Alvarez J.G., Thomazy V.A., and Evans R.M. PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 93 (1998) 241-252
186. Triantafilou M., Gamper F.G., Haston R.M., Mouratis M.A., Morath S., Hartung T., et al. Membrane sorting of toll-like receptor (TLR)-2/6 and TLR-2/1 heterodimers at the cell surface determines heterotypic associations with CD36 and intracellular targeting. J. Biol. Chem. 281 (2006) 31002-31011
187. van Berkel T.J., Out R., Hoekstra M., Kuiper J., Biessen E., and van Eck M. Scavenger receptors: Friend or foe in atherosclerosis?. Curr. Opin. Lipidol. 16 (2005) 525-535
188. van Nieuwenhoven F.A., Verstijnen C.P., Abumrad N.A., Willemsen P.H., Van Eys G.J., Van der Vusse G.J., et al. Putative membrane fatty acid translocase and cytoplasmic fatty acid-binding protein are co-expressed in rat heart and skeletal muscles. Biochem. Biophys. Res. Commun. 207 (1995) 747-752
189. van Weel V., de Vries M., Voshol P.J., Verloop R.E., Eilers P.H., van Hinsbergh V.W., et al. Hypercholesterolemia reduces collateral artery growth more dominantly than hyperglycemia or insulin resistance in mice. Arterioscler. Thromb. Vasc. Biol. 26 (2006) 1383-1390
190. Vistisen B., Roepstorff K., Roepstorff C., Bonen A., van Deurs B., and Kiens B. Sarcolemmal FAT/CD36 in human skeletal muscle colocalizes with caveolin-3 and is more abundant in type 1 than in type 2 fibers. J. Lipid Res. 45 (2004) 603-609
191. Voll R.E., Herrmann M., Roth E.A., Stach C., Kalden J.R., and Girkontaite I. Immunosuppressive effects of apoptotic cells. Nature 390 (1997) 350-351
192. Vosper H., Patel L., Graham T.L., Khoudoli G.A., Hill A., Macphee C.H., et al. The peroxisome proliferator-activated receptor delta promotes lipid accumulation in human macrophages. J. Biol. Chem. 276 (2001) 44258-44265
193. Watanabe K., Ohta Y., Toba K., Ogawa Y., Hanawa H., Hirokawa Y., et al. Myocardial CD36 expression and fatty acid accumulation in patients with type I and II CD36 deficiency. Ann. Nucl. Med. 12 (1998) 261-266
194. Wilkinson B., Koenigsknecht-Talboo J., Grommes C., Lee C.Y., and Landreth G. Fibrillar beta-amyloid-stimulated intracellular signaling cascades require Vav for induction of respiratory burst and phagocytosis in monocytes and microglia. J. Biol. Chem. 281 (2006) 20842-20850
195. Wilmsen H.M., Ciaraldi T.P., Carter L., Reehman N., Mudaliar S.R., and Henry R.R. Thiazolidinediones upregulate impaired fatty acid uptake in skeletal muscle of type 2 diabetic subjects. Am. J. Physiol. Endocrinol. Metab. 285 (2003) E354-E362
196. Wyler B., Daviet L., Bortkiewicz H., Bordet J.C., and McGregor J.L. Cloning of the cDNA encoding human platelet CD36: Comparison to PCR amplified fragments of monocyte, endothelial and HEL cells. Thromb. Haemost. 70 (1993) 500-505
197. XenneX Inc., GeneCards, http://www.genecards.org/cgi-bin/carddisp.pl?gene=CD36.
198. Yamamoto N., Akamatsu N., Sakuraba H., Yamazaki H., and Tanoue K. Platelet glycoprotein IV (CD36) deficiency is associated with the absence (type I) or the presence (type II) of glycoprotein IV on monocytes. Blood 83 (1994) 392-397
199. Yanai H., Chiba H., Morimoto M., Jamieson G.A., and Matsuno K. Type I CD36 deficiency in humans is not associated with insulin resistance syndrome. Thromb. Haemost. 83 (2000) 786
200. Yesner L.M., Huh H.Y., Pearce S.F., and Silverstein R.L. Regulation of monocyte CD36 and thrombospondin-1 expression by soluble mediators. Arterioscler. Thromb. Vasc. Biol. 16 (1996) 1019-1025
201. Yu S., Cao W.Q., Kashireddy P., Meyer K., Jia Y., Hughes D.E., et al. Human peroxisome proliferator-activated receptor alpha (PPARalpha) supports the induction of peroxisome proliferation in PPARalpha-deficient mouse liver. J. Biol. Chem. 276 (2001) 42485-42491
202. Zhang X., Fitzsimmons R.L., Cleland L.G., Ey P.L., Zannettino A.C., Farmer E.A., et al. CD36/fatty acid translocase in rats: Distribution, isolation from hepatocytes, and comparison with the scavenger receptor SR-B1. Lab Invest. 83 (2003) 317-332
203. Zhao M., Liu Y., Wang X., New L., Han J., and Brunk U.T. Activation of the p38 MAP kinase pathway is required for foam cell formation from macrophages exposed to oxidized LDL. APMIS 110 (2002) 458-468
204. Zhao G.F., Seng J.J., Zhang H., and She M.P. Effects of oxidized low density lipoprotein on the growth of human artery smooth muscle cells. Chin. Med. J. (Engl.) 118 (2005) 1973-1978
205. Zhou J., Zhai Y., Mu Y., Gong H., Uppal H., Toma D., et al. A novel pregnane X receptor-mediated and sterol regulatory element-binding protein-independent lipogenic pathway. J. Biol. Chem. 281 (2006) 15013-15020
206. Zuckerman S.H., Panousis C., Mizrahi J., and Evans G. The effect of gamma-interferon to inhibit macrophage-high density lipoprotein interactions is reversed by 15-deoxy-delta12,14-prostaglandin J2. Lipids 35 (2000) 1239-1247